Abbott is spending $21 billion to buy cancer testing company Exact Sciences, known for its Cologuard colorectal cancer at-home test in a box. Abbott’s purchase of Exact highlights the move toward consumer-friendly at-home cancer screenings.

Half of oncologists note their cancer patients are turning to AI tools for information before, during, and after their diagnosis and treatment, according to a recent survey of oncologists from Impiricus and Klick Health. As patients adopt more AI for health information, pharma marketers have a growing opportunity to help physicians navigate the new dynamic. Marketers can offer physicians training on how to discuss and correct AI-generated information, and by providing credible, easy-to-understand resources grounded in evidence.

The news: BioNTech is buying cancer vaccine researcher and one-time COVID-19 vaccine rival CureVac in a $1.25 billion all-stock deal. The takeaway: The new HHS is taking a less-than-positive view on mainstream vaccines and mRNA technology, but it’s also signaled strong interest in personalized medicines and novel therapies. That’s good news for BioNTech, and could be a sign to other pharmas and biotechs that precision and specialty drugs are poised for fast tracking, while vaccines caught up in public and political controversy will be overscrutinized and delayed to market.

Bristol Myers Squibb partners with BioNTech on new cancer drug: It’s the latest in a new class of cancer treatment drawing billions in dealmaking, which promises hope for cancer patients—but also likely higher drug prices.

Activist investor takes $1B stake in Pfizer, eyes a performance turnaround: But to the drugmaker’s credit, its plan to diversify the therapeutic areas it will focus on moving forward should place it in line with investors’ expectations.